ZVS101e

Phase 3Small molecule

CChigenovo Co., Ltd

ZVS101e is one of 129 small molecule programs targeting Bietti's Crystalline Dystrophy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

128

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bietti's Crystalline DystrophyNot yet recruiting

TreatmentEnrolling by invitation

Efficacy and SafetyRecruiting

Safety and EfficacyActive, not recruiting

Bietti's Crystalline DystrophyPreclinical

Not yet recruiting

TreatmentPreclinical

Enrolling by invitation

Efficacy and SafetyPhase 3

Recruiting

Safety and EfficacyPhase 2

Active, not recruiting

Competition

Competitive Landscape

350 competitors in Treatment

#DrugCompanyPhaseTrials

ZVS101e

CChigenovo Co., Ltd

Phase 3

1 2

Biltricide

Bayer

Preclinical

4 3

Dexilant

Takeda

Preclinical

2 4

Minipress

Pfizer

Preclinical

1 5

Levulan

Sun Pharmaceutical Industries, Inc.

Preclinical

1 6

Lamprene

Novartis

Preclinical

1 7

Foscavir

CClinigen, Inc.

Preclinical

6 8

Valium

Akero Therapeutics

Preclinical

2 9

Intuniv

PPromius Pharma, LLC

Preclinical

1 10

Reminyl

WWim Janssens

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1/2Active, not recruiting

Safety and Efficacy

NCT05832684

Q2 2030

Phase 3Recruiting

Efficacy and Safety

NCT06743646

Q4 2035

PreclinicalNot yet recruiting

Bietti's Crystalline Dystrophy

NCT07653971

Clinical

Trials by Indication[1]

Safety and Efficacy1 trial

Safety and Efficacy of ZVS101e in Patients With Bietti 's Crystalline Dystrophy

Active, not recruiting·CChigenovo Co., Ltd·Phase 1/2·NCT05832684·24 enrolled

Acute Lymphoblastic Leukemia1 trial

Safety and Tolerability of ZVS101e in Patients With Bietti 's Crystalline Dystrophy

Unknown status·PPeking University Third Hospital·Phase 1·NCT05714904·6 enrolled

Treatment1 trial

Compassionate Administration of ZVS101e Injection for Extended Treatment

Enrolling by invitation·CChigenovo Co., Ltd·N/A·NCT07307469·32 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of ZVS101e in Patients With Bietti 's Crystalline Dystrophy

Recruiting·CChigenovo Co., Ltd·Phase 3·NCT06743646·62 enrolled

Bietti's Crystalline Dystrophy1 trial

Clinical Translation and Application Protocol for ZVS101e in the Gene Therapy of Bietti Crystalline Corneoretinal Dystrophy

Not yet recruiting·CChigenovo Co., Ltd·Preclinical·NCT07653971·300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for ZVS101e. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ZVS101e compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ZVS101e. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Chigenovo Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CChigenovo Co., Ltd

ZVS101e

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q2 2030

Q4 2035

Trials by Indication[1]

Safety and Efficacy1 trial

Acute Lymphoblastic Leukemia1 trial

Treatment1 trial

Efficacy and Safety1 trial

Bietti's Crystalline Dystrophy1 trial

References

Drug Info

Quick Facts

Related News